Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Gross Profit (2016 - 2019)

Aptevo Therapeutics' Gross Profit history spans 5 years, with the latest figure at $2.9 million for Q4 2019.

  • For Q4 2019, Gross Profit changed N/A year-over-year to $2.9 million; the TTM value through Dec 2019 reached $12.5 million, changed N/A, while the annual FY2019 figure was $12.5 million, 5.43% up from the prior year.
  • Gross Profit for Q4 2019 was $2.9 million at Aptevo Therapeutics, down from $5.1 million in the prior quarter.
  • Across five years, Gross Profit topped out at $5.1 million in Q3 2019 and bottomed at -$2.6 million in Q4 2015.
  • The 5-year median for Gross Profit is $3.2 million (2016), against an average of $2.9 million.
  • The largest annual shift saw Gross Profit skyrocketed 241.61% in 2016 before it tumbled 63.21% in 2017.
  • A 5-year view of Gross Profit shows it stood at -$2.6 million in 2015, then surged by 241.61% to $3.7 million in 2016, then rose by 16.56% to $4.3 million in 2017, then dropped by 21.23% to $3.4 million in 2018, then fell by 14.53% to $2.9 million in 2019.
  • Per Business Quant, the three most recent readings for APVO's Gross Profit are $2.9 million (Q4 2019), $5.1 million (Q3 2019), and $1.4 million (Q2 2019).